CD200 and acute myeloid leukemia: Despite the different rate of expression in de novo and secondary AML, CD200 expression had a negative impact on OS in both groups; 3-year survival in CD200+ de novo cases (36%) was similar to that of CD200- secondary AML (39%), and significantly lower than CD200- de novo (49%) but higher than CD200+ secondary (11%) patients, respectively.